UPBUpstream Bio, Inc.
Pharmaceutical Preparations
- Revenue
- $3M
- 20% YoY
- Operating margin
- -5618.8%
- 71% YoY
- EBITDA
- −$160M
- 106% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired362% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear0% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|
| Revenue | $2M | $2M | $3M | 20% |
| Operating income | −$40M | −$78M | −$160M | 106% |
| Net income | −$21M | −$63M | −$143M | 128% |
| Operating cash flow | −$38M | −$59M | −$133M | 125% |
| Capex | $144K | $511K | $165K | 68% |
| Stock-based comp | $3M | $6M | $10M | 72% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $28K · 5
- Net
- −$28K
Pay vs performance
No pay-versus-performance disclosure yet.